CSF2 and infection: In a randomized trial published in 2005, GM-CSF treatment did not improve mortality but enhanced clinical and microbial resolution of infection as well as markers of monocytes and neutrophils functions (48); of note in this trial, patients with septic shock were excluded and significant proportion of patient had an organ transplant.